Hata, Tae
Sakaguchi, Chikara
Hirano, Keita
Kobe, Hiroshi
Ishida, Masaki
Nakano, Takayuki
Tachibana, Yusuke
Tamiya, Nobuyo
Shiotsu, Shinsuke
Takeda, Takayuki
Yamada, Tadaaki
Yokoyama, Toshihide
Tsuchiya, Michiko
Nagasaka, Yukio
Article History
Received: 2 May 2022
Accepted: 7 June 2022
First Online: 23 June 2022
Declarations
:
: Dr. Yamada received honoraria from Eli Lilly Japan K.K. and research funding from ONO Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., CHUGAI Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Inc. All other authors declare no conflicts of interest.
: This study was approved by the institutional review committee of each participating hospital. (the Institutional Review Board of Rakuwakai Otowa Hospital, the Medical Ethics Committee of Kurashiki Central Hospital, the Ethics Review Board of the Kyoto Prefectural University of Medicine, the Ethics Review Committee of Japanese Red Cross Kyoto Daini Hospital, and the Ethics Review Committee of Japanese Red Cross Kyoto Daiichi Hospital).
: This manuscript contains no individual’s personal data.